H-FEQNTAQP-NH2

Rif. 3D-PP44875

Informazioni sul prodotto

• Nome: H-FEQNTAQP-NH2
• Sinonimi: NH2-Phe-Glu-Gln-Asn-Thr-Ala-Gln-Pro-amide

Descrizione

Peptide H-FEQNTAQP-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-FEQNTAQP-NH2 include the following: A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling Y Xie, L Wang, A Freywald , M Qureshi - Cellular & molecular , 2013 - nature.comhttps://www.nature.com/articles/cmi201237 Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas Y Xie, H Zhang, W Li , Y Deng - The Journal of , 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/185/9/5268/83188 CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8-dendritic cells into IL-12-secreting immunogenic ones X Zhang, RM Kedl , J Xiang - Biochemical and Biophysical Research , 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006291X08025825 In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells X Lu, X Jiang, R Liu, S Zhang - Cancer immunology, immunotherapy, 2009 - Springerhttps://link.springer.com/article/10.1007/s00262-008-0573-7 Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response X Lu, X Jiang, R Liu, H Zhao, Z Liang - Cancer letters, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304383508004485 Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity X Cao, W Zhang, L He, Z Xie, S Ma, Q Tao - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/11/6238/44657 TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice W Zhang, H Yang, Z Wang, X Jim - Chinese medical journal, 2002 - mednexus.orghttps://mednexus.org/doi/abs/10.3760/cma.j.issn.0366-6999.2002.12.103 Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide W Zhang , L He, X Cao - Zhonghua yi xue za zhi, 1999 - europepmc.orghttps://europepmc.org/article/med/11601032 Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design V Apostolopoulos , M Yu, AL Corper, L Teyton - Journal of molecular , 2002 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022283602001961 MUC1 peptide epitopes associated with five different H-2 class I molecules V Apostolopoulos , JS Haurum - European journal of , 1997 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830271017 Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design V Apostolopoulos , IF McKenzie, IA Wilson - Front Biosci, 2001 - article.imrpress.comhttps://article.imrpress.com/bri/Landmark/articles/pdf/LandmarkA683.pdf Noncanonical peptides in complex with MHC class I V Apostolopoulos , E Lazoura - Expert Review of Vaccines, 2004 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/14760584.3.2.151 Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine T Kumamoto, EK Huang, HJ Paek, A Morita - Nature , 2002 - nature.comhttps://www.nature.com/articles/nbt0102-64 Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides S Nair, PA Wearsch , DA Mitchell - The Journal of , 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/162/11/6426/69376 A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells. S Malarkannan , M Afkarian, N Shastri - The Journal of experimental , 1995 - rupress.orghttps://rupress.org/jem/article-abstract/182/6/1739/25457 Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes S Hao, O Bai, J Yuan, M Qureshi , J Xiang - Cell Mol Immunol, 2006 - cmi.ustc.edu.cnhttp://www.cmi.ustc.edu.cn/3/3/205.pdf Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44+ CD62Lhigh IL-7R+ CTLs R Wang, A Freywald , Y Chen , J Xu, X Tan - Cellular & Molecular , 2015 - nature.comhttps://www.nature.com/articles/cmi201472 Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas. O Mandelboim, E Bar-Haim , E Vadai - (Baltimore, Md.: 1950 , 1997 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/159/12/6030/42563 Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis N Seo , Y Tokura , T Nishijima - Proceedings of the , 2000 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.97.1.371 Apolipoprotein B binding domains: evidence that they are cell-penetrating peptides that efficiently deliver antigenic peptide for cross-presentation of cytotoxic T cells N Sakamoto, AS Rosenberg - The Journal of Immunology, 2011 - journals.aai.orghttps://journals.aai.org/jimmunol/article/186/8/5004/84879 A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells J Xiang , H Huang, Y Liu - The Journal of Immunology, 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/174/12/7497/36992 Immunotherapy of spontaneous metastatic lung cancer with tumor antigen-pulsed, interleukin-12 gene-modified dendritic cells J Chen, Q Xiu, Z Yan, W Luo - Chinese Journal of Cancer Research, 2003 - Springerhttps://link.springer.com/article/10.1007/s11670-003-0023-1 CD4+ T cell-released exosomes inhibit CD8+ cytotoxic T-lymphocyte responses and antitumor immunity H Zhang, Y Xie, W Li , R Chibbar , S Xiong - Cellular & molecular , 2011 - nature.comhttps://www.nature.com/articles/cmi201059 Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity EE Tchekneva, MUL Goruganthu - for immunotherapy of , 2019 - Springerhttps://link.springer.com/article/10.1186/s40425-019-0566-4 CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion D Xia, S Hao, J Xiang - The Journal of Immunology, 2006 - journals.aai.orghttps://journals.aai.org/jimmunol/article/177/5/2976/37852 Role of chaperones in antigen processing CV Nicchitta - Immunological Investigations, 2000 - Taylor & Francishttps://www.tandfonline.com/doi/pdf/10.3109/08820130009062290 Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination B Tirosh , K el-Shami, N Vaisman, L Carmon - Immunology letters, 1999 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0165247899001157 Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. A Porgador , E Gilboa - The Journal of experimental medicine, 1995 - rupress.orghttps://rupress.org/jem/article-abstract/182/1/255/57639

• Marchio: Biosynth